Maternal serum placental leucine aminopeptidase as a predictor of pregnancy outcome
Background: Pregnancy leads to major physiological changes, which can cause complications like intrauterine fetal death, hypertensive disorders. Changes in placental leucine aminopeptidase serum levels may indicate placental dysfunction and associated risks for maternal health.
Aim of the study: To evaluate the relationship between maternal serum placental leucine aminopeptidase levels and pregnancy outcomes.
Patients and Methods: A case-control study involving 150 pregnant women was conducted in the Obstetrics and Gynecology department of Al- Khansaa and Al Batool Maternity teaching hospitals from January 1 to June 30, 2025. Participants were divided into three groups: Group 1 (25 cases of intrauterine fetal death), Group 2 (25 cases of hypertensive disorders) and Group 3 (100 healthy controls). Serum placental leucine aminopeptidase levels were measured to compare between cases and controls, adjusting for gestational age differences.
Results: Maternal serum placental leucine aminopeptidase levels were significantly lower in case groups compared with the control group (p < 0.001). The intrauterine fetal death group demonstrated the lowest of maternal serum placental leucine aminopeptidase levels. Significant differences were also observed in maternal age, body mass index, gravidity, and parity. Receiver operating characteristic analysis revealed excellent discriminative ability of maternal serum placental leucine aminopeptidase as a predictor of adverse pregnancy outcomes, with an area under the curve of 0.999 and cut-off points 812.7566.
Conclusion: Lower maternal serum placental leucine aminopeptidase levels were showed in complicated pregnancies, which may indicate negative pregnancy outcomes.